Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Bemnifosbuvir-Ruzasvir

Small molecule · Inhibitor of hepatitis C virus NS5B polymerase · developed by Atea Pharmaceuticals

Phase 3 Most advanced trial
AVIR Developer
2 Registered trials

What is Bemnifosbuvir-Ruzasvir?

Bemnifosbuvir-ruzasvir is an oral fixed-dose combination of bemnifosbuvir and ruzasvir, given once daily. It is studied in chronic hepatitis C virus infection, including patients with compensated cirrhosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
(BEM/RZR)
Drug type
Small molecule
Targets
hepatitis C virus NS5B polymerase
Mechanism
Inhibitor of hepatitis C virus NS5B polymerase
Therapy area
Infectious disease
Developer
Atea Pharmaceuticals, Inc. (AVIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07037277 Phase 3 HEPATITIS C VIRUS CHRONIC INFECTION Active not recruiting AVIR
NCT06868264 Phase 3 HEPATITIS C VIRUS CHRONIC INFECTION Active not recruiting AVIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis CHEPATITIS C VIRUS CHRONIC INFECTIONHepatitis C Virus InfectionHepatitis C, Chronic

More from Atea Pharmaceuticals

AT-527 Phase 1 AT-587 Phase 1 AT-752 Phase 2 AT-777 Phase 1/2 Bemnifosbuvir Phase 3 Ethinyl Estradioll/Levonorgestrel Phase 1 Ruzasvir Phase 2 Treatment A-Bemnifosbuvir/Ruzasvir FDC Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVIR page.

Follow AVIR, the company behind Bemnifosbuvir-Ruzasvir

See AVIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.